Opinion|Videos|December 17, 2024
Premature Treatment Discontinuation (Time to Response)
Author(s)Darren M. Brenner, MD, Amy Ladewski, PA-C
Thought leaders explore premature treatment discontinuation and some of the reasons leading to it, such as time to response and safety in regards to the use of prescription therapies for IBS-C and CIC.
Advertisement
Advertisement
Related to this article
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
2
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5